CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome
- 1Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico
- 2Laboratorio de Inmunobiología y Genética, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico
- 3Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico City, Mexico
- 4Departamento de Neuropatología, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suarez”, Mexico City, Mexico
- 5Department of Pathology, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico
- 6Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico
- 7Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Mexico City, Mexico
- 8Department of Virology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
- 9Subdirection of Surgery, Instituto Nacional deEnfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
- 10Departments of Dermatology and Education, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- 11Centro Especializado en Neurocirugía y Neurociencias México (CENNM), Mexico City, Mexico
- 12Departamento de Fibrosis Pulmonar, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico
- 13Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- 14Respiratory Critical Care Unit, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
- 15Department of Molecular Microbiology, Washington University School of Medicine in St Louis, St. Louis, MO, United States
- 16Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, CA, United States
A Corrigendum on
CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome
By Choreño-Parra JA, Jiménez-Álvarez LA, Ramírez-Martínez G, Sandoval-Vega M, Salinas-Lara C, Sánchez-Garibay C, Luna-Rivero C, Hernández-Montiel EM, Fernández-López LA, Cabrera-Cornejo MF, Choreño-Parra EM, Cruz-Lagunas A, Domínguez A, Márquez-García E, Cabello-Gutiérrez C, Bolaños-Morales FV, Mena-Hernández L, Delgado-Zaldivar D, Rebolledo-García D, Guadarrama-Ortiz P, Regino-Zamarripa NE, Mendoza-Milla C, García-Latorre EA, Rodríguez-Reyna TS, Cervántes-Rosete D, Hernández Cárdenas CM, Khader SA, Zlotnik A and Zúñiga J (2021). Front. Immunol. 12:633297. doi: .10.3389/fimmu.2021.633297
An author name was incorrectly spelled as Tatiana Sofia Rodiguez-Reyna. The correct spelling is Tatiana Sofía Rodríguez-Reyna.
In the published article, there was also an error in the affiliation of Criselda Mendoza-Milla. Instead of “Laboratorio de Inmunobiología y Genética, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico”, it should be “Departamento de Fibrosis Pulmonar, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico”.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: influenza A(H1N1), SARS-CoV-2, COVID-19, tuberculosis, chemokines, CXCL17
Citation: Choreño-Parra JA, Jiménez-Álvarez LA, Ramírez-Martínez G, Sandoval-Vega M, Salinas-Lara C, Sánchez-Garibay C, Luna-Rivero C, Hernández-Montiel EM, Fernández-López LA, Cabrera-Cornejo MF, Choreño-Parra EM, Cruz-Lagunas A, Domínguez A, Márquez-García E, Cabello-Gutiérrez C, Bolaños-Morales FV, Mena-Hernández L, Delgado-Zaldivar D, Rebolledo-García D, Guadarrama-Ortiz P, Regino-Zamarripa NE, Mendoza-Milla C, García-Latorre EA, Rodríguez-Reyna TS, Cervántes-Rosete D, Hernández-Cárdenas CM, Khader SA, Zlotnik A and Zúñiga J (2021) Corrigendum: CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome. Front. Immunol. 12:700716. doi: 10.3389/fimmu.2021.700716
Received: 26 April 2021; Accepted: 27 April 2021;
Published: 13 May 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Choreño-Parra, Jiménez-Álvarez, Ramírez-Martínez, Sandoval-Vega, Salinas-Lara, Sánchez-Garibay, Luna-Rivero, Hernández-Montiel, Fernández-López, Cabrera-Cornejo, Choreño-Parra, Cruz-Lagunas, Domínguez, Márquez-García, Cabello-Gutiérrez, Bolaños-Morales, Mena-Hernández, Delgado-Zaldivar, Rebolledo-García, Guadarrama-Ortiz, Regino-Zamarripa, Mendoza-Milla, García-Latorre, Rodríguez-Reyna, Cervántes-Rosete, Hernández-Cárdenas, Khader, Zlotnik and Zúñiga. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Joaquín Zúñiga, joazu@yahoo.com